Fig. 2.

EMG outcomes assessed in Patient 1 up to 12 months after systemic–intraosseous DT-DEC01 administration. EMG assessment of average MUP duration revealed: A increase in the deltoideus by 24.5 ± 8.3%, B preservation of MUP duration in the biceps brachii (97.5 ± 2.8% of baseline duration), C increase in the rectus femoris by 11.0 ± 5.4% and D significant increase in the gastrocnemius muscle by 52.6 ± 4.0% compared to baseline. The data are expressed as mean ± SEM, and the average of 10 MUP measurements is shown. The statistical significance was assessed by Kruskal–Wallis test, with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 denoting significant differences. V0a screening visit, V5 3-month, V6 6-month, V7 12-month visit after DT-DEC01 administration